search
Back to results

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Primary Purpose

Palmoplantar Pustulosis

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Deucravacitinib
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Palmoplantar Pustulosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: • Adults aged 18 years of age and older Dermatologist confirmed diagnosis of PPP for at least 6 months Moderate-severe PPP, defined as a ppPASI > 12 Inadequate response to topical therapy and a candidate for systemic or phototherapy Willing to discontinue current topical and/or systemic PPP treatments, except for OTC emollients Exclusion Criteria: • Participants with other immune-mediated conditions requiring concurrent systemic immunosuppressant treatments Current/recent administration of PPP-specific medications including: Rituximab within 6 months of the baseline visit Biologics within 12 weeks of baseline visit Systemic steroids, oral immunosuppressants (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tacrolimus), oral retinoids (acitretin, isotretinoin), apremilast, or dapsone within 4 weeks of baseline visit Phototherapy within 4 weeks of baseline visit Prescription topical medications (including calcineurin inhibitors, crisaborole, retinoids, steroids, tar, vitamin D analogs) within 2 weeks of baseline visit History of active infection and/or febrile illness within 7 days; or infection requiring antibiotic treatment within 30 days; or serious infection requiring hospitalization and/or IV antibiotics within 90 days Evidence of other infection including: Active or untreated latent tuberculosis, defined as radiographic or laboratory evidence of active TB or positive quantiferon or PPD, unless the subject has completed the recommended treatment Human immunodeficiency virus infection (positive HIV antibody) Active hepatitis B Active hepatitis C Evidence of clinically significant laboratory abnormality including: Absolute WBC count < 3000/mm3 Platelet count < 100,000/mm3 Hemoglobin < 9.0 g/dl ALT or AST > 3 times the upper limit of normal History of cancer within the past 5 years, excluding treated non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) Other uncontrolled chronic medical condition that may interfere with a patient's ability to participate in the clinical trial Major surgery within 4 weeks of baseline visit Receipt of live vaccine within 8 weeks of baseline visit Pregnant or breastfeeding individuals Inability to comply with any of the study procedures Individuals who are incarcerated or compulsory detained

Sites / Locations

  • Brigham and Women's HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Subjects with Palmoplantar pustulosis

Arm Description

All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Outcomes

Primary Outcome Measures

Proportion of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity

Secondary Outcome Measures

Proportion of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity
Change from baseline in the Dermatology Quality Life Index (DLQI)
The DLQI is a dermatology-specific quality of life instrument to measure the impact of skin disease on different aspects of health-related quality of life. The questionnaire contains 10 questions, each scored on a 4-point Likert scale. The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
Change from baseline in ppPASI
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity
Percentage of patient who achieve a Physicians Global Assessment Score of 0 or 1
The physician's global assessment is a widely used outcome measure that relies on physician visual assessment of disease severity. The static PGA determines psoriasis severity at a single point in time, without taking the baseline disease condition into clear (0), almost clear (1), mild (2), moderate (3), severe (4).
Change from baseline in EQ-5D VAS
The EQ-5D is a validated, reliable, and responsive instrument widely used in clinical trials where respondents rate their health in each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety depression. EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Change from baseline in the itch visual analogue scale (itch-VAS)
The VAS-itch is a 10 cm line on which patients mark their pruritus intensity on a scale from "no itch" (0 points) to "worst imaginable itch" (10 points). The VAS-itch can be interpreted as 0 - < 3 points represents mild pruritus, ≥ 3 - 7 points moderate pruritus, ≥ 7 - 9 points severe pruritus, and ≥ 9 points severe pruritus
Change from baseline in the pain visual analogue scale (pain-VAS)
The VAS-pain is a 10 cm line on which patients mark their pain on a scale from "no no" (0 points) to "worst imaginable pain" (100 points). The following cut points on the pain VAS have been recommended pain: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75 - 100 mm)

Full Information

First Posted
January 24, 2023
Last Updated
July 25, 2023
Sponsor
Brigham and Women's Hospital
Collaborators
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT05710185
Brief Title
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
Official Title
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2023 (Actual)
Primary Completion Date
December 1, 2025 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
Detailed Description
Objectives: Evaluate the efficacy of deucravacitinib in adults with PPP Evaluate the impact of deucravacitinib on quality of life in adults with PPP Evaluate the safety of deucravacitinib Primary Endpoint: • Proportion of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score, at 16 weeks Secondary Endpoints: • Proportion of participants who achieve at least 50% improvement in the palmoplantar pustular psoriasis area and severity index (ppPASI-50) at 24 weeks Frequency of participants with adverse events Change from baseline in the Dermatology Quality of Life Index Change from baseline in ppPASI Percentage of patients who achieved a static Physician's Global Assessment score of 0/1 Change from baseline in the EQ-5D VAS score Change from baseline in itch VAS Change from baseline in pain VAS Inclusion Criteria: • Adults aged 18 years of age and older Dermatologist confirmed diagnosis of PPP for at least 6 months Moderate-severe PPP, defined as a ppPASI > 12 Inadequate response to topical therapy and a candidate for systemic or phototherapy Willing to discontinue current topical and/or systemic PPP treatments, except for OTC emollients Exclusion Criteria: • Participants with other immune-mediated conditions requiring concurrent systemic immunosuppressant treatments Current/recent administration of PPP-specific medications including: Rituximab within 6 months of the baseline visit Biologics within 12 weeks of baseline visit Systemic steroids, oral immunosuppressants (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tacrolimus), oral retinoids (acitretin, isotretinoin), apremilast, or dapsone within 4 weeks of baseline visit Phototherapy within 4 weeks of baseline visit Prescription topical medications (including calcineurin inhibitors, crisaborole, retinoids, steroids, tar, vitamin D analogs) within 2 weeks of baseline visit History of active infection and/or febrile illness within 7 days; or infection requiring antibiotic treatment within 30 days; or serious infection requiring hospitalization and/or IV antibiotics within 90 days Evidence of other infection including: Active or untreated latent tuberculosis, defined as radiographic or laboratory evidence of active TB or positive quantiferon or PPD, unless the subject has completed the recommended treatment Human immunodeficiency virus infection (positive HIV antibody) Active hepatitis B Active hepatitis C Evidence of clinically significant laboratory abnormality including: Absolute WBC count < 3000/mm3 Platelet count < 100,000/mm3 Hemoglobin < 9.0 g/dl ALT or AST > 3 times the upper limit of normal History of cancer within the past 5 years, excluding treated non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) Other uncontrolled chronic medical condition that may interfere with a patient's ability to participate in the clinical trial Major surgery within 4 weeks of baseline visit Receipt of live vaccine within 8 weeks of baseline visit Pregnant or breastfeeding individuals Inability to comply with any of the study procedures Individuals who are incarcerated or compulsory detained Sample Size: A modified Simon's two-stage design will be used to maximize the safety and efficiency of this clinical trial in an orphan disease. In the first stage, 8 patients will be accrued. If 2 or fewer patients achieve a ppPASI-50 in these 8 patients, the study will be stopped. Otherwise, 10 additional patients will be accrued for a total of 18. Analysis Plan: Descriptive statistics will be used to characterize the study population, including demographics, disease characteristics and previous treatments. For the primary outcome, the percentage of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score, at 16 weeks, the response rate with a 95% CI will be calculated. For all secondary endpoints, summary and descriptive statistics will be used as appropriate , including number of observations, calculation of mean/median, standard deviation range and 95% confidence intervals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Palmoplantar Pustulosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Subjects with Palmoplantar pustulosis
Arm Type
Experimental
Arm Description
All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Deucravacitinib
Intervention Description
See arm/group description
Primary Outcome Measure Information:
Title
Proportion of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score
Description
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Proportion of participants who achieve a ppPASI-50 response, or at least 50% improvement in ppPASI score
Description
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity
Time Frame
Week 24
Title
Change from baseline in the Dermatology Quality Life Index (DLQI)
Description
The DLQI is a dermatology-specific quality of life instrument to measure the impact of skin disease on different aspects of health-related quality of life. The questionnaire contains 10 questions, each scored on a 4-point Likert scale. The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
Time Frame
Week 16, Week 24
Title
Change from baseline in ppPASI
Description
The ppPASI is the most commonly used disease severity measure use in palmoplantar pustulosis clinic trials. The ppPASI is composed of subscores of erythema (E), pustules/vesicles (P), desquamation/scales (D) on the left (L) and right (R) palm (P) and sole (S) respectively. The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity
Time Frame
Week 16, Week 24
Title
Percentage of patient who achieve a Physicians Global Assessment Score of 0 or 1
Description
The physician's global assessment is a widely used outcome measure that relies on physician visual assessment of disease severity. The static PGA determines psoriasis severity at a single point in time, without taking the baseline disease condition into clear (0), almost clear (1), mild (2), moderate (3), severe (4).
Time Frame
Week 16, Week 24
Title
Change from baseline in EQ-5D VAS
Description
The EQ-5D is a validated, reliable, and responsive instrument widely used in clinical trials where respondents rate their health in each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety depression. EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Time Frame
Week 16, Week 24
Title
Change from baseline in the itch visual analogue scale (itch-VAS)
Description
The VAS-itch is a 10 cm line on which patients mark their pruritus intensity on a scale from "no itch" (0 points) to "worst imaginable itch" (10 points). The VAS-itch can be interpreted as 0 - < 3 points represents mild pruritus, ≥ 3 - 7 points moderate pruritus, ≥ 7 - 9 points severe pruritus, and ≥ 9 points severe pruritus
Time Frame
Week 16, Week 24
Title
Change from baseline in the pain visual analogue scale (pain-VAS)
Description
The VAS-pain is a 10 cm line on which patients mark their pain on a scale from "no no" (0 points) to "worst imaginable pain" (100 points). The following cut points on the pain VAS have been recommended pain: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75 - 100 mm)
Time Frame
Week 16, 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Adults aged 18 years of age and older Dermatologist confirmed diagnosis of PPP for at least 6 months Moderate-severe PPP, defined as a ppPASI > 12 Inadequate response to topical therapy and a candidate for systemic or phototherapy Willing to discontinue current topical and/or systemic PPP treatments, except for OTC emollients Exclusion Criteria: • Participants with other immune-mediated conditions requiring concurrent systemic immunosuppressant treatments Current/recent administration of PPP-specific medications including: Rituximab within 6 months of the baseline visit Biologics within 12 weeks of baseline visit Systemic steroids, oral immunosuppressants (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tacrolimus), oral retinoids (acitretin, isotretinoin), apremilast, or dapsone within 4 weeks of baseline visit Phototherapy within 4 weeks of baseline visit Prescription topical medications (including calcineurin inhibitors, crisaborole, retinoids, steroids, tar, vitamin D analogs) within 2 weeks of baseline visit History of active infection and/or febrile illness within 7 days; or infection requiring antibiotic treatment within 30 days; or serious infection requiring hospitalization and/or IV antibiotics within 90 days Evidence of other infection including: Active or untreated latent tuberculosis, defined as radiographic or laboratory evidence of active TB or positive quantiferon or PPD, unless the subject has completed the recommended treatment Human immunodeficiency virus infection (positive HIV antibody) Active hepatitis B Active hepatitis C Evidence of clinically significant laboratory abnormality including: Absolute WBC count < 3000/mm3 Platelet count < 100,000/mm3 Hemoglobin < 9.0 g/dl ALT or AST > 3 times the upper limit of normal History of cancer within the past 5 years, excluding treated non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) Other uncontrolled chronic medical condition that may interfere with a patient's ability to participate in the clinical trial Major surgery within 4 weeks of baseline visit Receipt of live vaccine within 8 weeks of baseline visit Pregnant or breastfeeding individuals Inability to comply with any of the study procedures Individuals who are incarcerated or compulsory detained
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Liset Chacin
Phone
6172645926
Email
lchacin@bwh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Alex Gionfriddo
Email
agionfriddo@bwh.harvard.edu
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liset Chacin, BS
Phone
617-264-5926
Email
lchacin@bwh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Mary O'Donnell
Email
MODONNELL6@mgh.harvard.edu

12. IPD Sharing Statement

Learn more about this trial

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

We'll reach out to this number within 24 hrs